Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors
Chemical Biology & Drug Design · 2024-01 · 103 (1)
DOI: 10.1111/cbdd.14425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 11.12.2023. Verfasst von Xiaoyong Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Environment and Quality Inspection, Chongqing Chemical Industry Vocational College, Chongqing, China. Hauptthemen laut MEDLINE: COVID-19, Coronavirus 3C Proteases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Science and Technology Research Project of Chongqing Education Commission (No. KJQN202304510, KJQN202204506)..
Abstract (Originalsprache)
The pneumonia outbreak caused by Severe Acute Respiratory Syndrome 2 (SARS‐CoV‐2) infection poses a serious threat to people worldwide. Although vaccines have been developed, antiviral drugs are still needed to combat SARS‐CoV‐2 infection due to the high mutability of the virus. SARS‐CoV‐2 main protein (M pro ) is a special cysteine protease that is a key enzyme for SARS‐CoV‐2 replication. It is encoded by peptides and is responsible for processing peptides into functional proteins, making it an important drug target. The paper reviews the structure and peptide‐like inhibitors of SARS‐CoV‐2 M pro , also the binding mode and structure–activity relationship between the inhibitors and M pro are introduced in detail. It is hoped that this review can provide ideas and help for the development of anti‐coronavirus drugs such as COVID‐19, and help to develop broad‐spectrum antiviral drug for the treatment of coronavirus diseases as soon as possible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Environment and Quality Inspection, Chongqing Chemical Industry Vocational College, Chongqing, China.
- Chongqing Experimental School, Chongqing, China.
- Biomedical Analysis and Testing Center, College of Basic Medicine, Third Military Medical University, Chongqing, China.
Förderung
- Science and Technology Research Project of Chongqing Education Commission (No. KJQN202304510, KJQN202204506).
Zitieren
APA
Liu, X., Ren, X., Hua, M., Liu, F., Ren, X., Sui, C., Li, Q., Luo, F., Jiang, Z., Xia, Z., Chen, J., & Yang, B. (2024). Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors. Chemical Biology & Drug Design, 103(1). https://doi.org/10.1111/cbdd.14425
Vancouver
Liu X, Ren X, Hua M, Liu F, Ren X, Sui C, et al. Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors. Chemical Biology & Drug Design. 2024;103(1). doi:10.1111/cbdd.14425
BibTeX
@article{Liu2024,
author = {Liu, Xiaoyong and Ren, Xiaoli and Hua, Miao and Liu, Fang and Ren, Xiaoping and Sui, Chaoya and Li, Qing and Luo, Fen and Jiang, Zhiyong and Xia, Ziqiao and Chen, Jingxia and Yang, Bing},
title = {Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors},
journal = {Chemical Biology & Drug Design},
year = {2024},
volume = {103},
number = {1},
doi = {10.1111/cbdd.14425}
}
EUVIMED